Xilio Therapeutics Announces $50M Public Offering

Xilio Therapeutics ( (XLO) ) has issued an announcement.

On June 2, 2025, Xilio Therapeutics announced the pricing of a $50 million underwritten public offering involving pre-funded warrants and Series A, B, and C warrants to purchase shares of common stock. The company expects to receive approximately $46.6 million in net proceeds, which will be used to advance product development and meet general corporate needs. The offering is expected to close around June 5, 2025, and is subject to customary closing conditions. This strategic move is anticipated to extend Xilio’s financial runway through the third quarter of 2026, enhancing its operational capabilities and market positioning.

The most recent analyst rating on (XLO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Xilio Therapeutics stock, see the XLO Stock Forecast page.

Spark’s Take on XLO Stock

According to Spark, TipRanks’ AI Analyst, XLO is a Neutral.

Xilio Therapeutics receives a moderate score due to a mix of promising strategic partnerships and ongoing financial challenges. The partnership with AbbVie is a notable positive, providing potential financial and strategic benefits. However, the company’s current lack of profitability and negative cash flow impact the overall evaluation. Technical analysis indicates short-term momentum, but longer-term trends remain a concern. The valuation reflects the company’s current unprofitability.

To see Spark’s full report on XLO stock, click here.

More about Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company focused on discovering and developing tumor-activated immuno-oncology therapies aimed at improving outcomes for cancer patients while minimizing systemic side effects. The company utilizes a proprietary platform to create novel, tumor-activated molecules that enhance therapeutic efficacy within the tumor microenvironment.

Average Trading Volume: 1,207,260

Technical Sentiment Signal: Buy

Current Market Cap: $36.25M

Find detailed analytics on XLO stock on TipRanks’ Stock Analysis page.